Cerevel Therapeutics Holdings, Inc. Stock price
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.37 USD | -0.02% | +0.13% | -0.18% |
Mar. 25 | Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation | MT |
Mar. 04 | Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.7B |
---|---|---|---|---|---|
Net income 2024 * | -456M | Net income 2025 * | -551M | EV / Sales 2024 * | - |
Net cash position 2024 * | 709M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-17
x | P/E ratio 2025 * |
-15.2
x | Employees | 334 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 41.95% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | -0.29% | ||
1 week | -0.05% | ||
Current month | +3.05% | ||
1 month | +2.50% | ||
3 months | -0.45% | ||
6 months | +90.57% | ||
Current year | -0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 43 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Deval Patrick
BRD | Director/Board Member | 67 | 21-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 42.33 | -0.12% | 476 054 |
24-03-27 | 42.38 | +0.05% | 889,388 |
24-03-26 | 42.36 | -0.09% | 1,296,694 |
24-03-25 | 42.4 | +0.50% | 1,564,304 |
24-03-22 | 42.19 | -0.19% | 707,439 |
Delayed Quote Nasdaq, March 28, 2024 at 10:48 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.35% | 7.7B | |
+3.36% | 108B | |
+9.41% | 104B | |
+6.46% | 23.66B | |
-11.65% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-13.44% | 16.19B | |
+4.69% | 13.72B | |
+34.16% | 12.22B |